Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

被引：0
|
作者：
Akira Sawaki
Yasuhide Yamada
Yoshito Komatsu
Tatsuo Kanda
Toshihiko Doi
Masato Koseki
Hideo Baba
Yu-Nien Sun
Koji Murakami
Toshirou Nishida
机构：
[1] Aichi Cancer Center Hospital,Department of Gastroenterology
[2] National Cancer Center Hospital,Gastrointestinal Oncology Division
[3] Hokkaido University Hospital,Department of Gastroenterology
[4] Niigata University Hospital,Digestive and General Surgery 2 Division
[5] National Cancer Center Hospital East,Division of Gastrointestinal Oncology
[6] National Hospital Organization Kure Medical Center,Department of Surgery
[7] Kumamoto University Hospital,Department of Surgical Pathology
[8] Amgen Inc.,Department of Pharmacokinetics and Drug Metabolism
[9] Dokkyo University School of Medicine,PET Center
[10] Osaka University Hospital,Department of Digestive Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 65卷
关键词：
Motesanib; Angiogenesis inhibitor; Gastrointestinal stromal tumor (GIST);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：961 / 967
页数：6
相关论文
共 50 条
  • [21] Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
    Kanda, Tatsuo
    Nishida, Toshirou
    Wada, Norihito
    Kobayashi, Osamu
    Yamamoto, Masakazu
    Sawaki, Akira
    Boku, Narikazu
    Koseki, Masato
    Doi, Toshihiko
    Toh, Yasushi
    Kakeji, Yoshihiro
    Sugiyama, Toshiro
    Komatsu, Yoshito
    Kikuchi, Shojiro
    Ogoshi, Kyoji
    Katai, Hitoshi
    Miyachi, Kazuhito
    Hirota, Seiichi
    Ohtsu, Atsushi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (01) : 38 - 45
  • [22] Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs)
    Byrd, D. M.
    Demetri, G. D.
    Joensuu, H.
    von Mehren, M.
    Heinrich, M.
    Eisenberg, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Imatinib mesylate in advanced chordoma: A multicenter phase II study
    Stacchiotti, S.
    Ferrari, S.
    Ferraresi, V.
    Grignani, G.
    Crippa, F.
    Messina, A.
    Spreafico, C.
    Tamborini, E.
    Gronchi, A.
    Casali, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate
    Yeh, Chun-Nan
    Chen, Tsung-Wen
    Wu, Ting-Jung
    Hsueh, Swei
    Jan, Yi-Yin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (23) : 3760 - 3765
  • [25] Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate
    Kun-Chun Chiang
    Tsung-Wen Chen
    Chun-Nan Yeh
    Hsiang-Lin Lee
    World Journal of Gastroenterology, 2006, (13) : 2060 - 2064
  • [26] Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate
    Chun-Nan Yeh
    Tsung-Wen Chen
    Ting-Jung Wu
    Swei Hsueh
    Yi-Yin Jan
    World Journal of Gastroenterology, 2006, (23) : 3760 - 3765
  • [27] Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate
    Chiang, Kun-Chun
    Chen, Tsung-Wen
    Yeh, Chun-Nan
    Liu, Feng-Yuan
    Lee, Hsiang-Lin
    Jan, Yi-Yin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (13) : 2060 - 2064
  • [28] The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors
    DeCaprio, James A.
    Duensing, Anette
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (04) : 415 - 421
  • [29] Imaging of Gastrointestinal Stromal Tumors before and after Imatinib Mesylate Therapy
    Shankar, S.
    Dundamadappa, S. K.
    Karam, A. R.
    Stay, R. M.
    van Sonnenberg, E.
    ACTA RADIOLOGICA, 2009, 50 (08) : 837 - 844
  • [30] FDG-PET as a surrogate marker for response to Gleevec™ (imatinib mesylate) in patients with advanced gastrointestinal stromal tumors (GIST).
    Van den Abbeele, AD
    Badawi, RD
    Tetrault, RJ
    Cliche, JP
    Manola, J
    Spangler, T
    Janicek, MJ
    Israel, DA
    Heinrich, MC
    Silberman, SS
    Dimitrijevic, S
    Demetri, GD
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 24P - 25P
12345